What is Encellin?
Founded in 2015, Encellin is pioneering a novel approach to regenerative medicine by developing advanced cell transplant therapy. Their proprietary soft cell encapsulation device (CED) is designed to protect transplanted cells, allowing them to survive and function effectively within the patient's body. This technology holds potential for treating a range of conditions, with initial focus on metabolic disorders such as hypoglycemia and hypocalcemia. The company's strategy centers on creating 'smart molecular factories' that release therapeutics precisely when needed, addressing unmet needs in chronic disease management.
How much funding has Encellin raised?
Encellin has raised a total of $15.8M across 2 funding rounds:
Angel/Seed
$5.9M
Other Financing Round
$9.9M
Angel/Seed (2021): $5.9M with participation from Sandhill Angels, SV Latam Capital, Y Combinator, and Khosla Ventures
Other Financing Round (2023): $9.9M led by Khosla Ventures and Y Combinator
Key Investors in Encellin
SV Latam Capital
SV LATAM Capital is an early-stage venture capital firm based in Silicon Valley, focusing on Latin American entrepreneurs and science/technology startups that aim to solve significant global problems, including healthcare advancements.
Y Combinator
Y Combinator is a renowned startup accelerator and seed funding provider, established in 2005, that supports early-stage businesses and connects them with investors.
Khosla Ventures
Khosla Ventures is a prominent venture capital firm that invests in a wide range of technology sectors, known for backing innovative startups with transformative potential.
What's next for Encellin?
With the recent major strategic investment, Encellin is poised to accelerate its development and commercialization efforts. The substantial capital infusion, particularly the recent strategic financing, suggests a transition towards scaling operations and advancing its pipeline candidates through clinical trials. This enterprise-level backing indicates strong investor confidence in Encellin's technology and its potential to disrupt the regenerative medicine market. Future growth will likely involve expanding its therapeutic applications and solidifying strategic partnerships to bring its innovative CED technology to patients.
See full Encellin company page
